Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxercalciferol Dosing by PTH Ratio in ESRD
NCT00502268Phase 4Withdrawn
- Sponsor
- Southeast Renal Research Institute
- Start
- Feb 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of doxercalciferol in secondary hyperparathyroidism (SHPT), sponsored by Southeast Renal Research Institute. Planned start Feb 2008; status: withdrawn.
02
Drugs
doxercalciferol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00502268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502268.